1211534-27-8

Basic information

• Product Name: 5-Fluoro-2-Methoxy-3-nitropyridine
• Synonyms: 5-Fluoro-2-Methoxy-3-nitropyridine
• CAS NO: 1211534-27-8
• Molecular Formula: C6H5FN2O3
• Molecular Weight: 172.1139032
• Mol File: 1211534-27-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 5-Fluoro-2-Methoxy-3-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluoro-2-Methoxy-3-nitropyridine(1211534-27-8)
• EPA Substance Registry System: 5-Fluoro-2-Methoxy-3-nitropyridine(1211534-27-8)

Safety Data

• Hazardous Substances Data: 1211534-27-8(Hazardous Substances Data)

Usage

General Description

5-Fluoro-2-Methoxy-3-nitropyridine is a chemical compound with the molecular formula C6H5FN2O3. It is a nitro derivative of pyridine that contains a fluorine atom and a methoxy group. 5-Fluoro-2-Methoxy-3-nitropyridine is a yellow crystalline solid that is primarily used in the synthesis of pharmaceuticals and agrochemicals. It is also used as an intermediate in the production of various organic compounds. Additionally, 5-Fluoro-2-Methoxy-3-nitropyridine is known for its potential as a building block in the development of new materials and chemical products. However, it is important to handle this chemical with care due to its potential hazardous properties.

Upstream product

• 136888-20-5 5-fluoro-2-hydroxy-3-nitropyridine 
• 74-88-4 methyl iodide 
• 51173-05-8 5-fluoropyridin-2-ol 

Downstream Products

• 1211541-93-3 5-fluoro-2-methoxy-pyridin-3-amine 

Relevant articles and documents

Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases

Janus kinases (JAKs) have a key role in regulating the expression and function of relevant inflammatory cytokines involved in asthma and chronic obstructive pulmonary disease. Herein are described the design, synthesis, and pharmacological evaluation of a series of novel purinone JAK inhibitors with profiles suitable for inhaled administration. Replacement of the imidazopyridine hinge binding motif present in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure-activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34, a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced rat model of airway inflammation by the inhaled route.

Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases

New pyridin-2(1h)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).